Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers

  • World J Clin Oncol. 2024 May 24;15(5):603-613. doi: 10.5306/wjco.v15.i5.603.
Zheng-Long Wu  1  2 ,  Ying Wang  1 ,  Xiao-Yuan Jia  1 ,  Yi-Gang Wang  3 ,  Hui Wang  2
Affiliations
  • 1. Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China.
  • 2. Department of Oncology, Zhejiang Xiaoshan Hospital, Hangzhou 311201, Zhejiang Province, China.
  • 3. Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China. [email protected].
PMID: 38835843 DOI: 10.5306/wjco.v15.i5.603
Abstract

Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) is a member of the type I receptor tyrosine kinase family. ROR1 is pivotal in embryonic development and Cancer, and serves as a biomarker and therapeutic target. It has soluble and membrane-bound subtypes, with the latter highly expressed in tumors. ROR1 is conserved throughout evolution and may play a role in the development of gastrointestinal Cancer through multiple signaling pathways and molecular mechanisms. Studies suggest that overexpression of ROR1 may increase tumor invasiveness and metastasis. Additionally, ROR1 may regulate the cell cycle, stem cell characteristics, and interact with Other signaling pathways to affect Cancer progression. This review explores the structure, expression and role of ROR1 in the development of gastrointestinal cancers. It discusses current antitumor strategies, outlining challenges and prospects for treatment.

Keywords
Antitumor strategies; Gastrointestinal cancers; Molecular mechanisms; Receptor tyrosine kinase-like orphan receptor 1; Therapeutic target.
Products